,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,19849,3,3,,103169262,107678,Unspecified,,,,,Maximum reversion frequency,Other,3959029.0,
1,20508,3,4,,103169262,107678,Unspecified,,,,,Chromatographic measure of drug lipophilicity,Other,6688830.0,
2,20511,3,4,,103169262,107678,Unspecified,,,,,Lipophilicity (Rm) (liquid chromatography),Other,6747989.0,
3,20524,3,4,,103169262,107678,Unspecified,,,,,Relative measure (Rm) of lipophilic/hydrophilic balance from partition chromatography,Other,6988589.0,
4,24208,3,3,,103169262,107678,Unspecified,,,,,Association constant for binding to poly [d(A-T)],Other,7205885.0,
5,24209,3,3,,103169262,107678,Unspecified,,,,,Association constant for binding to poly [d(G-C)],Other,7205885.0,
6,25311,3,3,,103169262,107678,Unspecified,,,,,Acid dissociation constant was determined,Other,6688830.0,
7,25559,3,3,,103169262,107678,Unspecified,,,,,Ionization constant (pKa),Other,7069706.0,
8,25575,3,4,,103169262,107678,Unspecified,,,,,Dissociation constant in aqueous DMF.,Other,6546591.0,
9,25641,5,2,,103169262,107678,Unspecified,,,,,Half life of the drug was determined in the presence of 2-mercaptoethanol,Other,6688830.0,
10,26064,3,4,,103169262,107678,Unspecified,,,,,Ionization constant (pKa),Other,6988589.0,
11,26375,3,3,,103169262,107678,Unspecified,,,,,Ionisation constant (pKa),Other,7205885.0,
12,26528,3,3,,103169262,107678,Unspecified,,,,,Binding affinity towards poly[d(A-T)] (fluorometric method),Other,6747989.0,
13,26537,3,3,,103169262,107678,Unspecified,,,,,log K value (Logarithm of DNA-affinity association constant),Other,3959029.0,
14,26599,3,3,,103169262,107678,Unspecified,,,,,Dissociation constant (pKa),Other,3959029.0,
15,26756,3,4,,103169262,107678,Unspecified,,,,,DNA binding dissociation constant as KD,Other,6708048.0,
16,46149,7,1,,103169262,107678,Active,,,,,Inhibitory concentration against ethidium binding to DNA,Other,7205885.0,
17,54456,3,3,,103169262,107678,Unspecified,,,,,Binding constant to poly (dA-dT) was determined in calf thymus DNA by a fluorometric method,Other,6688830.0,
18,55124,3,3,,103169262,107678,Unspecified,,,,,Binding constant for DNA by ethidium bromide displacement,Other,6546591.0,
19,95454,6,2,,103169262,107678,Active,,,1.0,IC50,"Concentration required to reduce growth of human jurkat leukemia cells to 50% of control cultures, determined using a 72 hr continuous exposure",Confirmatory,8182707.0,
20,96632,5,1,,103169262,107678,Active,,,0.035,ID50,In vitro test for 50% reduction of cell number (of control) after 70 hr incubation with cultures of murine L1210 leukemia cells,Confirmatory,6747989.0,
21,96646,5,1,,103169262,107678,Active,,,0.035,ID50,Concentration for inhibiting the growth of L1210 cells by 50% over 3 days was determined,Confirmatory,7143362.0,
22,98490,4,5,,103169262,107678,Active,,,0.035,IC50,Inhibitory concentration to reduce the growth of L1210 cells by 50% after 70 hr.,Confirmatory,3820217.0,
23,98699,5,1,,103169262,107678,Active,,,0.035,ID50,Reduce in the cell count when drug added to the murine L1210 leukemia cell cultures for 70 h,Confirmatory,6688830.0,
24,98819,4,5,,103169262,107678,Unspecified,,,,,Drug concentration in mole/kg/day providing 50% extension of life in intraperitoneally implanted leukemia L1210 mice.,Other,7069706.0,
25,100306,3,4,,103169262,107678,Unspecified,,,,,Dose of the drug (mol /kg) providing a 50% life extension in L1210 assays when given at qd 1-5 schedule.,Other,3820217.0,
26,101091,5,1,,103169262,107678,Active,,,0.035,ID50,In vitro concentration required to inhibit the growth of L1210 cells in culture by 50% following a 48 hr exposure.,Confirmatory,6546591.0,
27,116415,3,3,,103169262,107678,Unspecified,,,,,Maximum percent increase in life span of mice was determined by L1210 assay,Other,7205885.0,
28,116709,5,2,,103169262,107678,Unspecified,,,,,Drug dose that is lethal to 10% of animals was measured,Other,7205885.0,
29,117342,5,2,,103169262,107678,Unspecified,,,,,Percentage increase in life span of drug-treated tumor bearing controls was determined,Other,6546591.0,
30,119953,3,5,,103169262,107678,Unspecified,,,,,Dose of drug given intraperitoneally on a qd 1-5 schedule that provides the highest ILS value in mice bearing 10E6 ip inoculated L1210 leukemia cells,Other,6546591.0,
31,132896,3,3,,103169262,107678,Unspecified,,,,,"Percent increase in the life span of treated mice over a group of control mice injected with p388 tumor alone when administered intraperitoneally (66) as a solution in 0.1 mL of 30%,v/v, ethanol/water",Other,6688830.0,
32,134224,3,5,,103169262,107678,Unspecified,,,,,"In vivo toxicity (qd 1-5), determined using the intraperitoneal implantation of L1210 leukemia cells in mice",Other,6988589.0,
33,139092,3,4,,103169262,107678,Unspecified,,,,,Drug dose in (mg/kg)/day to provide an increase in life span of 40% was determined,Other,6988589.0,
34,139101,3,4,,103169262,107678,Unspecified,,,,,Percent increase in life span in L1210 assay at the LD10 dose,Other,6988589.0,
35,150215,3,4,,103169262,107678,Unspecified,,,,,In vivo dose of drug needed for a percentage increase of 50% in life span of tumor-bearing mice compared to untreated controls after inoculation of 10e6 P388 leukemia cells,Other,6747989.0,
36,150694,5,1,,103169262,107678,Active,,,0.04,ID50,Concentration for inhibiting the growth of P-388 cells by 50% over 3 days was determined,Confirmatory,7143362.0,
37,152520,3,5,,103169262,107678,Unspecified,,,,,In vivo tumor cell selectivity (ILSmax values)for percentage increase in life span of treated animals over that of P388 tumor bearing untreated control animals,Other,6747989.0,
38,152668,3,5,,103169262,107678,Unspecified,,,,,In vivo inhibition of P388 in mice for optimal (highest nonacutely toxic) dose (OD),Other,6747989.0,
39,153025,3,6,,103169262,107678,Unspecified,,,,,Optimal dose administered intraperitoneally in,Other,6688830.0,
40,153878,3,4,,103169262,107678,Unspecified,,,,,Percentage increase in life span was measured for P-388 cells in culture after intraperitoneal administration of a dose of 150 mg/kg,Other,7143362.0,
41,158039,6,2,,103169262,107678,Active,,,3.0,IC50,Inhibitory concentration IC50 against Plasmodium falciparum K1 by [3H]hypoxanthine uptake over 24 hr,Confirmatory,8182707.0,
42,162407,3,3,,103169262,107678,Unspecified,,,,,Antitumor activity as association constant for DNA binding to poly (dA.dT),Other,7143362.0,
43,201226,3,4,,103169262,107678,Unspecified,,,,,"The mutagenic effectiveness, lowest molar concentration required for a constant proportion of revertant colonies (chosen as 50 per 10E8 bacteria)",Other,6988589.0,
44,201229,3,4,,103169262,107678,Unspecified,,,,,Concentration of drug needed to kill Salmonella Typhimurium strain TA 1537 grown on histidine-enriched medium,Other,6988589.0,
45,201364,3,4,,103169262,107678,Unspecified,,,,,"Mutagenic efficiency, measured as the concentration providing 50% inhibition of Salmonella Typhimurium strain TA 1537 growth in drug induced-mutant colonies",Other,6988589.0,
46,210614,4,3,,103169262,107678,Unspecified,,,,,Compound concentration in mole/kg/day lethal to 10% of mice,Other,7069706.0,
47,235013,3,4,,103169262,107678,Unspecified,,,,,In vitro therapeutic index value is the ratio between IC50 values of [J] and [P],Other,8182707.0,
48,1132612,1,1,,103169262,107678,Unspecified,,,,,Logarithmic function of the retardation factor value of compound by reverse phase chromatography analysis,Other,660586.0,
49,1132613,1,1,,103169262,107678,Unspecified,,,,,Toxicity in ip dosed C3H/DBA2F1 hybrid mouse allografted with mouse L1210 cells administered for 5 days measured up to 8 days,Other,660586.0,
50,1132614,1,1,,103169262,107678,Unspecified,,,,,Antitumor activity against mouse L1210 cells allografted in C3H/DBA2F1 hybrid mouse assessed as maximum increase of host life span administered as ip for 5 days relative to control,Other,660586.0,
51,1133942,1,1,,103169262,107678,Unspecified,,,,,"Lipophilic-hydrophilic balance, Rm of the compound by reversed-phase partition chromatography",Other,850238.0,
52,1133943,1,1,,103169262,107678,Unspecified,,,,,Half life of the compound in 0.1 M mercaptoethanol buffer at pH 7.4 at 37 degC by thiolytic assay,Other,850238.0,
53,1133944,1,1,,103169262,107678,Unspecified,,,,,Toxicity in ip dosed mouse assessed as optimum dose that providing maximum increase in life span administered qd for 1 to 5 days,Other,850238.0,
54,1133945,1,1,,103169262,107678,Unspecified,,,,,Antitumor activity against mouse L1210 cells subcutaneously xenografted in ip dosed C3H/DBA2 F1 hybrid mouse assessed as increase in host lifespan administered daily for 5 days starting 24 hrs post-tumor implantation,Other,850238.0,
55,1133946,1,1,,103169262,107678,Unspecified,,,,,Antitumor activity against mouse L1210 cells intraperitoneally xenografted in ip dosed C3H/DBA2 F1 hybrid mouse assessed as increase in host lifespan administered daily for 5 days starting 24 hrs post-tumor implantation,Other,850238.0,
56,1134704,1,1,,103169262,107678,Unspecified,,,,,Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as increase in life span at optimal dose administered qd from day 1 to 5 of challenge relative to control,Other,903915.0,
57,1134705,1,1,,103169262,107678,Unspecified,,,,,"Ionization constant, pKa of the compound in 20% DMF-buffer mixture by UV spectrophotometry",Other,903915.0,
58,1134706,1,1,,103169262,107678,Unspecified,,,,,"Lipophilic-hydrophilic balance, Rm of the compound by reversed-phase partition chromatography",Other,903915.0,
59,1134708,1,1,,103169262,107678,Unspecified,,,,,Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as dose required for maximum increase in life span administered qd from day 1 to 5 of challenge,Other,903915.0,
60,1148372,1,1,,103169262,107678,Unspecified,,,,,"Dissociation constant, basic pKa of the compound by UV spectrophotometry",Other,619148.0,
61,1148373,1,1,,103169262,107678,Unspecified,,,,,"Lipopholic-hydrophilic balance, Rm of the compound by reversed-phase chromatography",Other,619148.0,
62,1148374,1,1,,103169262,107678,Unspecified,,,,,Antitumor activity against mouse L1210 cells transfected in ip dosed C3H/DBA2 F1 mouse qd administered for 5 days,Other,619148.0,
63,1148375,1,1,,103169262,107678,Unspecified,,,,,Antitumor activity against mouse L1210 cells transfected in C3H/DBA2 F1 mouse assessed as increase in life span at optimum dose administered ip qd for 5 days relative to control,Other,619148.0,
64,1148471,1,1,,103169262,107678,Active,,,,,Displacement of ethidium bromide from calf thymus DNA by spectrofluorometric analysis,Other,671464.0,
65,1148473,1,1,,103169262,107678,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in ip dosed BDF1 mouse at optimum dose administered qd for 5 days relative to control,Other,671464.0,
66,1148474,1,1,,103169262,107678,Unspecified,,,,,Antitumor activity against mouse L1210 cells allografted in ip dosed BDF1 mouse at optimum dose administered qd for 5 days relative to control,Other,671464.0,
67,1148475,1,1,,103169262,107678,Unspecified,,,,,Toxicity in ip dosed BDF1 mouse allografted with mouse P388 cells administered qd for 5 days,Other,671464.0,
68,1148476,1,1,,103169262,107678,Unspecified,,,,,Toxicity in ip dosed BDF1 mouse allografted with mouse L1210 cells administered qd for 5 days,Other,671464.0,
69,1148477,1,1,,103169262,107678,Unspecified,,,,,"Lipophilic-hydrophilic balance, Rm of the compound by reversed-phase chromatographic analysis",Other,671464.0,
70,1149743,1,1,,103169262,107678,Unspecified,,,,,Half life in mouse L1210 cells allografted C3H/DBA2 F1 hybrid hybrid mouse,Other,894684.0,
71,1149744,1,1,,103169262,107678,Unspecified,,,,,"Retardation factor, Rm of the compound by reversed phase partition chromatography",Other,894684.0,
72,1149745,1,1,,103169262,107678,Unspecified,,,,,Toxicity in sc implanted mouse L1210 cells allografted C3H/DBA2 F1 hybrid hybrid mouse assessed as optimum dose required to increase life span treated ip after 24 hrs after tumor inoculation and continued for 5 days,Other,894684.0,
73,1149746,1,1,,103169262,107678,Unspecified,,,,,Antileukemic activity against sc implanted mouse L1210 cells in C3H/DBA2 F1 hybrid hybrid mouse assessed as increase life span treated ip after 24 hrs after tumor inoculation and continued for 5 days,Other,894684.0,
74,1149747,1,1,,103169262,107678,Unspecified,,,,,Antileukemic activity against ip implanted mouse L1210 cells in C3H/DBA2 F1 hybrid hybrid mouse assessed as increase life span treated ip after 24 hrs after tumor inoculation and continued for 5 days,Other,894684.0,
75,1150100,1,1,,103169262,107678,Unspecified,,,,,"Ionization constant, pKa of the compound by UV spectrophotometric analysis",Other,926112.0,
76,1150101,1,1,,103169262,107678,Unspecified,,,,,Antitumor activity against mouse L1210 cells allografted in ip dosed C3H X DBA2 F1 mouse assessed as optimum dose required to cause greatest life extension administered as qd for 5 days,Other,926112.0,
77,1150102,1,1,,103169262,107678,Unspecified,,,,,"Antitumor activity against mouse L1210 cells allografted through ip in C3H X DBA2 F1 mouse assessed as increase in life span at optimum dose, ip qd administered for 5 days relative to control",Other,926112.0,
78,1150103,1,1,,103169262,107678,Unspecified,,,,,"Antitumor activity against mouse L1210 cells allografted through sc in C3H X DBA2 F1 mouse assessed as increase in life span at optimum dose, ip qd administered for 5 days relative to control",Other,926112.0,
79,1150556,1,1,,103169262,107678,Unspecified,,,,,Antitumor activity against mouse L1210 cells allografted in ip dosed C3H/DBA2 F1 mouse assessed as optimum dose required to increase in maximum life span administered as qd for 5 days,Other,950644.0,
80,1150557,1,1,,103169262,107678,Unspecified,,,,,"Antitumor activity against mouse L1210 cells allografted in C3H/DBA2 F1 mouse assessed as increase in life span at optimum dose, ip qd administered for 5 days relative to control",Other,950644.0,
81,1259407,1,1,,363902496,107678,Active,,,,,CCRIS mutagenicity studies,Other,,
